SCHEMBL4930855

SCHEMBL4930855

CCCCOc1ccc(-n2c(=O)[nH]c3cc(Cl)c(Cl)cc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.49
MEN1 O00255 2/20 0.48
LMNA P02545 2/20 0.48
KMT2A Q03164 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2D6 P10635 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 2/20 0.48
NFKB1 P19838 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
MAOB P27338 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
GRIA1 P42261 1/20 0.40
GRIA2 P42262 1/20 0.40
GRIA3 P42263 1/20 0.40
GRIA4 P48058 1/20 0.40
METAP2 P50579 1/20 0.40
GPR84 Q9NQS5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4931144 0.95 LMNA (0.48) HRH3MEN1LMNAKMT2ACYP1A2
SCHEMBL4928439 0.90 MEN1 (0.50) HRH3MEN1LMNAKMT2ACYP1A2
SCHEMBL4928761 0.86 L3MBTL1 (0.47) HRH3MEN1LMNAKMT2ACYP1A2
SCHEMBL4929970 0.86 L3MBTL1 (0.60) HRH3MEN1LMNAKMT2ACYP1A2
SCHEMBL11342123 0.86 MAOB (0.53) HRH3CYP1A2CYP3A4CYP2D6TSHR
SCHEMBL4934267 0.83 ATM (0.54) MEN1LMNAKMT2ACYP1A2CYP3A4
SCHEMBL4931086 0.81 L3MBTL1 (0.47) HRH3MEN1LMNAKMT2ACYP1A2
SCHEMBL4933122 0.81 L3MBTL1 (0.60) HRH3MEN1LMNAKMT2ACYP1A2
SCHEMBL4929992 0.76 KMT2A (0.63) HRH3MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL4933166 0.76 MEN1 (0.49) MEN1LMNAKMT2ASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 HRH3 1274/4885MEN1 4097/4885LMNA 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.